WO2004096852A1 - Interferon$g(v) humain recombinant, son procede d'expression et ses utilisations - Google Patents

Interferon$g(v) humain recombinant, son procede d'expression et ses utilisations Download PDF

Info

Publication number
WO2004096852A1
WO2004096852A1 PCT/CN2004/000374 CN2004000374W WO2004096852A1 WO 2004096852 A1 WO2004096852 A1 WO 2004096852A1 CN 2004000374 W CN2004000374 W CN 2004000374W WO 2004096852 A1 WO2004096852 A1 WO 2004096852A1
Authority
WO
WIPO (PCT)
Prior art keywords
interferon
recombinant human
sequence
protein
seq
Prior art date
Application number
PCT/CN2004/000374
Other languages
English (en)
Chinese (zh)
Inventor
Wei Chen
Lianquan Qi
Ling Fu
Changming Yu
Dazhi Lai
Original Assignee
The Institute Of Microbiology And Epidemiology, Academy Of Military Medical Sciemces, Pla
Taiji Group Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 03123298 external-priority patent/CN1444993A/zh
Priority claimed from CNA03123299XA external-priority patent/CN1539971A/zh
Application filed by The Institute Of Microbiology And Epidemiology, Academy Of Military Medical Sciemces, Pla, Taiji Group Co., Ltd. filed Critical The Institute Of Microbiology And Epidemiology, Academy Of Military Medical Sciemces, Pla
Priority to CN200480011049.1A priority Critical patent/CN1777620A/zh
Publication of WO2004096852A1 publication Critical patent/WO2004096852A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a recombinant human ⁇ interferon and its expression method and application in the field of genetic engineering, in particular to a recombinant human ⁇ interferon, an expression method of the interferon and its prevention and / or treatment caused by coronavirus Of medicines for diseases.
  • Human ⁇ interferon was discovered in 1985. It is a class of interferon molecules with similar functions to ⁇ interferon but different antigenicity (Hauptmann R, Swetly P. A novel class of human type I interferons [J]. Nucleic Acids Res, 1985 , 13 (13): 4739-4749.) D. Using a standard antiviral test, the specific activity of human ⁇ interferon has been determined to be 2.7- 4 X 108U / mg. Induced by Sendai virus, human peripheral blood leukocytes have been successfully used to produce and purify human omega interferon
  • Pichia pastoris is a eukaryotic expression system established in recent years (Cereghino JL, Cregg J M. Heterologous protein expression in the methylotrophic yeast Pichia pastorisij. FEMS Microbiol Rev, 2000, 24 (1): 45-66.), Is one of the most successful expression systems for expressing foreign proteins. Because it has prokaryotic expression systems, such as the commonly used E. coli expression system, it has the characteristics of rapid reproduction, low cost and convenient operation, and it has the advantages of eukaryotic expression system that can correctly process, fold and moderate glycosylation of the expressed protein. It also has the advantage of easy purification of recombinant protein. It is therefore becoming more and more widely used for the large-scale expression of proteins.
  • the Pichia pastoris expression system includes two modes: intracellular expression and secretory expression.
  • the secretory expression is highly expressed, the glycosylation is complete, the disulfide bond and the advanced structure are formed correctly, especially the subsequent isolation and purification is very popular. .
  • Pichia yeast is a methanol nutritional yeast, which grows rapidly, has simple culture conditions, and can be continuously cultured at high density. Its genetic operation is similar to that of Saccharomyces cerevisiae, and its technology is quite mature.
  • the promoter (pAOXl) is an inducible promoter, which is inhibited by glucose, and transcription and translation only begin after induction by methanol, which is very suitable for the expression of foreign genes.
  • PPIC9K is a multi-copy secreted expression vector introduced by Invitrogen.
  • the size is 9.3 kb.
  • the vector contains E. coli replication origin Col El, ampicillin, and kanamycin resistance genes.
  • the kanamycin resistance gene can also make Pichia pastoris resistant to G418, which can be used for the screening of multiple copy insertions.
  • PPIC9K uses the secretion signal of alpha factor to secrete the target gene to the outside. Since Pichia yeast only secretes about 5% of the total protein to the outside, it is very convenient to isolate and purify the expressed protein. However, the exogenous protein expressed by the secretory expression vector PPIC9K will have incorrect N-terminus.
  • Severe Acute Respiratory Syndrome the pathogen of which is a newly emerged virus, is a variant of coronavirus, and has a homology of about 60% with the known coronavirus gene sequence, but its antigenicity There is no overlap between the two. So although the antibody-positive rate of coronavirus in the normal population is above 50%, there is no protective effect against this virus, which leads to the general susceptibility of the population. The virus causes severe respiratory diseases, and the case fatality rate currently reaches 4%, which seriously endangers human health. Finding effective prevention and treatment drugs for SARS virus has become a top priority for the medical community.
  • the object of the present invention is to provide a recombinant human ⁇ interferon and its coding gene.
  • the recombinant human ⁇ interferon provided by the present invention is derived from human Homo sapiens) and is named rHuIFN- ⁇ . It is a protein having the sequence of SEQ ID Ns: 2 amino acid residues in the sequence listing, or it is SEQ ID No : 2 A protein derived from SEQ ID Na : 2 after substitution, deletion or addition of one or more amino acid residues and having the same activity as the amino acid residue sequence of SEQ ID No : 2.
  • Sequence 2 in the sequence listing is a protein consisting of 174 amino acid residues.
  • rHuIFN- ⁇ Recombinant human ⁇ interferon coding gene, named rHuIFN- ⁇ , it is one of the following nucleotide sequences:
  • the DNA sequence of Sequence 1 in the Sequence Listing is composed of 525 bases, and the reading frame of the gene is from the 1st to 525th bases at the 5 'end.
  • Both the expression vector and the cell line containing the gene of the present invention belong to the protection scope of the present invention.
  • Different recombinant expression vectors and engineering bacteria can be obtained by using existing molecular biology methods, such as the recombinant expression vector ⁇ 9 ⁇ ⁇ (the map is shown in Figure 1 ) And Pichia yeast GS115 containing the gene of the present invention.
  • a second object of the present invention is to provide a method for expressing recombinant human omega interferon.
  • the method for expressing recombinant human "interferon" provided by the present invention is to introduce a recombinant expression vector containing the above-mentioned recombinant human ⁇ interferon-encoding gene into an expression host, and express the recombinant human ⁇ interferon.
  • the host may be yeast, E. coli, mammalian cells, insect cells, Bacillus subtilis, Lactobacillus, etc., preferably yeast, particularly Pichia pastoris, and most preferably Pichia pastoris. Red yeast GS115.
  • the content of the target protein reached the maximum 48-60 hours after induction, accounting for 20% -30% of the total protein in the culture supernatant.
  • the purity of the target protein can be more than 95%, and the recovery rate is more than 30%.
  • the expression vector for inserting the above-mentioned recombinant human ⁇ interferon-encoding gene may be a vector expressed in the above host, such as pET, pQE, which can be expressed in E. coli, and pMEX9K, which can be expressed in Pichia yeast. And pPIC9K, among which pMEX9K is preferred.
  • a recombinant expression vector containing the above-mentioned recombinant human ⁇ interferon-encoding gene can be constructed according to a conventional method.
  • a third object of the present invention is to provide a medicament for preventing and / or treating a disease caused by a coronavirus.
  • the medicament for preventing and / or treating diseases caused by coronavirus provided by the present invention its active ingredient is recombinant human ⁇ interferon.
  • the coronavirus is preferably a SARS virus.
  • the recombinant human ⁇ interferon is preferably glycosylated, such as a glycosylated recombinant human ⁇ interferon expressed in a Pichia expression system.
  • the Pichia pastoris expression system is preferably a secretory expression system, such as the expression vectors pMEX9K, pPIC9K.
  • the medicament of the present invention can be administered by injection or mucosa, and can be made into various medicaments such as injections, sprays or nasal drops.
  • the above various dosage forms can be prepared according to the conventional methods in the pharmaceutical field.
  • the dosage of the above drugs is generally 1000IU-4000IU of recombinant human ⁇ interferon / kg body weight / day.
  • Figure 1 is a schematic diagram of the construction process of recombinant human ⁇ interferon expression vector
  • Figure 2 is an SDS-PAGE map of the Pichia transformant expression product
  • Figure 3 is an SDS-PAGE chart of recombinant human ⁇ interferon after digestion with glycosidase PNGase F.
  • Figure 4 is a photo of the protective effect of recombinant human ⁇ interferon and IFN- ⁇ on SARS virus attacked VER0-E6 cells.
  • Figure 5 is a photo of spray administration
  • Figure 6 is an anesthetic challenge photo
  • Figure 7a is a photo of lung lesions in the drug group on day 6 after challenge
  • Figure 7b is a picture of lung lesions in the placebo group on day 6 after challenge.
  • Figure 8a is a photo of lung lesions in the drug group on day 16 after challenge
  • Figure 8b is a photograph of the lung lesions in the placebo group on the 16th day after challenge
  • Figure 9a is a photograph of the spleen tissue lesions in the drug group on the 16th day after challenge
  • Figure 9b is a photograph of spleen tissue lesions in the placebo group on day 16 after challenge.
  • Fig. 10a is a 50 X observation photo of the lung pathological tissue on the 16th day after challenge in the placebo group.
  • Fig. 10b is a 50 X observation photo of the lung pathological tissue on the 16th day after the challenge in the drug group.
  • Figure ib is the 25 X observation photos of the spleen pathology on the 16th day after challenge in the drug group.
  • Figure 12 is a typical of the cell culture supernatant in the placebo group.
  • Figures 13-14 are electron micrographs of alveolar epithelial cells on day 6 after challenge in the placebo group.
  • Figure 15 is an electron micrograph of spleen lymphocytes on day 6 after challenge in the placebo group.
  • E. coli DH5 ⁇ , Pichia pastoris were purchased from Huamei Company.
  • Restriction enzymes T 4 DNA ligase, plasmid extraction and recovery kits and pGEMT vectors were purchased from Promega.
  • the primers were synthesized by Shanghai Shengong Company.
  • FICOLL, TRIZOL, and agarose were purchased from Huamei Company.
  • YNB is a product of Difico.
  • Low molecular weight standard protein is a product of Amersham Pharmacia.
  • the glycosidase PNGase F was purchased from New England Biolabs.
  • MEM medium and newborn bovine serum were purchased from Hyclone.
  • E. coli medium LB medium 1% peptone, 1% sodium chloride, 0.5% yeast extract powder; LBAK medium: ampicillin and kanamycin were added to the LB medium to a final concentration of 100 g / mL.
  • Yeast medium YPD medium 1% yeast extract powder, 1% peptone, 2% glucose.
  • BMGY medium 1% yeast extract, 1% peptone, 1. 34 YNB, 1% glycerol, 100ramol / L phosphate buffer pH6.0, 4X10- 5% biotin.
  • BMMY medium 1% yeast extract powder, 1% peptone, 1.34% YNB, 1% methanol, 100mmol / L phosphate buffer pH 6.0, 4X10
  • Cell culture medium MEM medium is used, and 3% -10% of newborn bovine serum is added.
  • FIC0LL reagent was used to isolate white blood cells from human blood, total RNA was extracted with TRIZ0L, and the human ⁇ interferon gene was amplified by conventional RT-PCR methods.
  • the primer sequence for PCR amplification was
  • the obtained amplified product was ligated into a pGEMT vector to obtain a recombinant plasmid pGEMTc plasmid.
  • the sequencing results showed that the recombinant human ⁇ interferon gene has a cDNA sequence as shown in Sequence 1 in the Sequence Listing, which encodes an amino acid residue sequence as shown in Sequence Listing 2.
  • the Xho I cleavage point was introduced by using the primer with sequence 3 (amplifying the 5 'end of human ⁇ interferon in the sequence listing), and the CTG codons at positions 15-17 of 5 from the 5' end in sequence 3 encode the human ⁇ interferon.
  • a codon) and sequence 4 amplify the 3 'end of human ⁇ interferon, introduce the Eco RI cleavage point
  • the primers of the nucleotide sequence shown by PCR method from the plasmid carrying the human ⁇ interferon gene The gene was amplified on pGEMTc.
  • Xho I and EcoR ⁇ digestion vector pMEX9K Qi Lianquan, Chen Wei, Yu Changming et al.
  • Recombinant plasmid ⁇ 9 ⁇ DNA was digested with 53 ⁇ 4 ⁇ , separated, purified, recovered, and transformed by electrotransformation Pichia GS115.
  • the transformed GS115 by MD (MD medium: 1. 34% YNB, 2% glucose, 4X 10- 5% biotin) to give hi s + plate screening of recombinant clones, each clone in the MD while o'clock, plates bandit (Band culture medium: 1. 34% YNB, 0.5% methanol, 4X 10-5 % biotin), culture at 30 ° C for 2-3 days, and determine the Mut phenotype of each strain.
  • MD MD medium: 1. 34% YNB, 2% glucose, 4X 10- 5% biotin
  • the three recombinant clones with higher expression levels were inoculated into 5ml BMGY, and cultured at 30 ° C and 300r / min to 0D 6 . . It is 2.0-6. 0; centrifugation at room temperature of 6,000 r / min for 4 min. The cells were collected and diluted with 0D 6 to BMMY suspension. . After 1.0, induction at 300 ° C / min at 30 ° C. Add methanol to 0..5% every 12h. The culture supernatant was collected 48 hours after induction, and protein expression was measured by SDS-PAGE and its biological activity was determined.
  • the results of the activity assay showed that the supernatant activities of the three positive clones were 3.2 X 10 6 , 1. 6 X 10 n 3. 0 X 10 6 U / mL; the results of protein expression detected by SDS-PAGE are shown in Figure 2
  • the protein band at 22,000 is the target protein, and the molecular weight of the protein is larger than the theoretical molecular weight, which is speculated to be caused by glycosylation. (In the amino acid sequence of the target protein, there is a potential glycosylation site Asn80-Met81 -Thr82).
  • lane ab c is the expression supernatant of the transformant after induction; lane if d is the expression supernatant of the transformant before induction; lane e is the target protein; lane m is a low molecular weight standard protein.
  • the bacterial solution 48 hours after induction in step 2 was centrifuged at 10,000 r / min for 10 minutes, and the supernatant was filtered through a 0.45Mm filter membrane and applied to a large particle cation chromatography column (SP Sepharose XL pre-equilibrated with sodium acetate).
  • the target protein peak was eluted with 0.5M sodium chloride; the target protein peak was loaded on a hydrophobic chromatography column (Phenyl HighSub, Amersham Biosciences), and the eluted peak was loaded on a small particle ion exchange column (Source 30S , Amersham Biosciences), 500 mol / L sodium chloride elutes the target protein peak; the target protein peak is loaded on a Superdex 75 gel filtration column, and the target protein is eluted with 20 mmol / L PBS, 150 mol / L sodium chloride, pH 7.2 peak.
  • the results are shown in lane a in Figure 3. The target protein was well separated. It was found by thin-layer scanning that the target protein was more than 95% pure.
  • the purified target protein was digested with glycosidase PNGase F.
  • the results are shown in Figure 3, which indicates that the molecular weight of the recombinant human ⁇ interferon is about 20, 300 Daltons, indicating that the molecular weight of the target protein is greater than the theoretical molecular weight for glycosylation.
  • lane a is the target protein purified in step 3;
  • lane b is a recombinant human ⁇ interferon obtained after digestion with PNGase F glycosidase;
  • lane c is a PNGase F glycosidase;
  • lane m is a protein molecular weight standard.
  • the relative molecular mass of the protein determined by MALDI-TOF is basically consistent with the theoretical value (Matrix-assisted laser desorption time of flight (MALDI-TOF) mass spectrometry to determine the molecular weight of the target protein before and after PNGase F digestion is 22, 166. 10 and 20, 340. 71).
  • the amino acid residues of the amino terminus of the recombinant human ⁇ interferon were determined.
  • the sequence is: LGCDLPQNHGLLSRN. It shows that the recombinant human ⁇ interferon has the amino acid sequence of amino terminal which is consistent with the natural protein.
  • Example 3 Protective effect of the recombinant human ⁇ -interferon of the present invention on SARS coronavirus attack Virus source: SARS Coronavirus BJ01 [J] (Qin Ede, Zhu Qingyu, Yu Man et al., Full sequence of SARS-associated virus (BJ01 strain) And its comparative analysis. Science Bulletin, 2003, 48 (11): 1127-1134), diluted 1:20 for use.
  • the recombinant human ⁇ interferon used in this example is a recombinant human ⁇ interferon glycoprotein expressed by Pichia pastoris GS115 in Example 1.
  • IFN- ⁇ is derived from Rebif, a recombinant product of CH0 cells marketed abroad.
  • rHuIFN- ⁇ human ⁇ interferon
  • VER0-E6 cells at a concentration of 250 000 ml / 96 well plate were seeded, 5% C0 2, 37 ° C culture 4- 6hr, the recombinant human interferon ⁇ or IFN- ⁇ culture of the present invention is added to the same concentration 20h, except Add 100 ⁇ 1 virus to each well of HI- H6 The solution was cultured until the virus control was completely diseased, and crystal violet staining was performed. The results are shown in FIG. 4, which shows that the recombinant human ⁇ interferon of the present invention and IFN- ⁇ have similar anti-SARS virus activity.
  • A1-G1 and A2-G2 add 10,000 IU / ml of the recombinant human ⁇ interferon of the present invention to each well; the concentrations of the recombinant human ⁇ interferon of the present invention added to A3-G3 and A4-G4 are A3 and A4 in this order.
  • A5-G5 and A6-G6 concentration of the recombinant human ⁇ interferon of the present invention added by A5-G5 and A6-G6 is 10000IU / ml in sequence of A5 and A6; 2000IU / ml of B5 and B6; 400IU / ml of C5 and C6; D5 and D6 80IU / ml; E5 and E6 are 16IU / ml; F5 and F6 are 3.2IU / ml; G5 and G6 are 0.64IU / ml; A7-G7 and A
  • the dose was the same as that for human use, namely 2 million IU / 8ml, and the left and right nostrils were 0.1 ml, once a day, and then Anesthesia challenge (Figure 6), nasal spray once a day after challenge; placebo group was given the same dose of spray dilution.
  • the challenge strain was BJ01, and the challenge dose was 1 ml (10 7 TCID 5 o / ral). Animals were dissected on days 6 and 16 after challenge.
  • Placebo group On the 6th day after challenge, the dissection revealed that the lungs were dark pink, the surface of the lung was uneven, and large lobules or large patches of bleeding spots were seen on the apex of multiple lungs (Figure 7b); on the 16th day after challenge, Pulmonary apical bleeding It is more obvious, the bleeding is wider, the lungs are dark red, the surface of the lungs is uneven, and the alveoli with emphysema can be seen protruding from the surface of the lung ( Figure 8b); the splenomegaly is obvious, dark brown, the edges are blunt, There were white hyperplastic spleen body nodules (Figure 9b); no other organs showed significant changes.
  • Severe inflammatory sites are characterized by severe exudative inflammation, manifested by necrosis and shedding of alveolar and small bronchial epithelial cells, a large number of lymphocytes, alveolar macrophages, neutrophil infiltration, and a large number of red blood cells in the alveolar space, occasionally mixed fibrin
  • the proteinous exudate, the entire lung tissue structure was destroyed, adjacent alveolar compensatory emphysema, multiple alveolar cavities were ruptured, and merged into a large cavity (Figure 10a).
  • the cynomolgus monkey's pulmonary interstitial capillaries were slightly dilated and congested, and the symptoms of pneumonia were mild.
  • the pulmonary interstitial capillaries and alveolar capillaries were congested with a small amount of lymphocytes and macrophages.
  • Infiltration Figure 10b).
  • Lymph nodes On the 6th day after challenge, the lymph node lymphocytes of the cynomolgus monkeys in the placebo group slightly proliferated and the number of lymphatic follicles increased; On the 16th day after the challenge, the lymph node lymphocytes proliferated more prominently, and the lymphocytes were dense and the lymphoid follicles The number increases. Lymph node lymphocytes in cynomolgus monkeys in the drug group also proliferated, but they were not as significant as those in the challenge group over the same period.
  • Spleen The cynomolgus monkey in the placebo group was erythrocytes and sinus congestion on the 6th day after challenge, and the spleen body lymphocytes were slightly proliferated; on the 16th day after challenge, the spleen body lymphocyte proliferation was more obvious, and the number of spleen bodies The number of lymphocytes in the germinal center of the spleen was increased, and the lymphocytes were arranged closely (Figure 11a). The spleen lymphocytes of the drug group showed mild hyperplasia (Figure lib).
  • Liver After the challenge, the lobular liver structure of the cynomolgus monkey in the drug group was intact, and hepatocyte granule degeneration and vesicular degeneration were seen in the lobule, and a few hepatocytes were fatty degeneration; while in the placebo group, the cynomolgus monkey's hepatocyte granules were degenerated, and central vein congestion in the manifold area Occasionally, thrombosis was observed, and a transparent membrane was also formed in the central vein of the hepatic manifold area. A small amount of lymphocytes infiltrated in the manifold area, and the Kupffer cells of the liver slightly proliferated.
  • Myocardium The cynomolgus monkeys in the placebo group were congested under the myocardial fibers of the myocardium, and the focal granular degeneration of the myocardial fibers was more pronounced, especially in the epicardium and subendocardium. transsexual.
  • Kidney In the placebo group, the renal tubule epithelial cells of the cynomolgus monkey degenerate or necrosis, and the epithelial cells fall off; in the drug group, the renal tubular epithelial cells of the cynomolgus monkey degenerate.
  • the cytoplasmic endoplasmic reticulum of alveolar epithelium and spleen lymphocytes of cynomolgus monkeys in the placebo group expanded, coronavirus particles sprouted from the endoplasm, and a large number of coronavirus particles were seen in the cytoplasm of the cells.
  • the diameter of the virus particles 80-120nm, the electron density at the center of the virion is low ( Figure 13-15, bar 100 dishes).
  • the lower right corner is partially enlarged, showing a typical coronavirus particle.
  • cynomolgus monkey lung epithelial cells and spleen lymphocytes occasionally swelled mitochondria, increased cytoplasmic vacuoles, and no typical coronavirus particles were seen.
  • the cynomolgus monkey in the placebo group was inoculated with BJ01 strain of coronavirus.
  • BJ01 strain of coronavirus On the 6th and 16th days, it was found that there were large rice grains or large bleeding spots on the apex of multiple lung lobules. Histopathological observation showed that cynomolgus monkeys developed interstitial pneumonia. Severe inflammatory sites are characterized by severe exudative inflammation, manifested by necrosis and shedding of alveolar and small bronchial epithelial cells, a large number of lymphocytes, alveolar macrophages, neutrophil infiltration, and a large number of red blood cells in the alveolar space, occasionally mixed fibrin Proteinaceous exudate.
  • coronavirus particles 80-120 nm in diameter, were observed in the alveolar epithelial cells and spleen lymphocyte cytoplasm.
  • a typical coronavirus is isolated from the lungs. This is consistent with the pathological changes in human SARS patients, indicating that cynomolgus monkeys can be used as animal models for studying SARS pathology.
  • the cynomolgus monkey in the drug group was also inoculated with a large dose of BJ01 strain of coronavirus. Due to the application of the recombinant human omega interferon spray of the present invention, compared with the placebo group, the animals in the drug group had less pathological damage to the lungs. Coronavirus particles were observed and no coronavirus was isolated from the viscera. It shows that the recombinant human ⁇ interferon of the present invention can effectively inhibit the proliferation of SARS virus in the body and reduce the damage to the body.
  • the recombinant human ⁇ interferon of the present invention has a potential glycosylation site A S n80-Met81- Thr82, Recombinant human ⁇ interferon expressed by Pichia pastoris is a glycosylated protein with good thermal stability. The validity period is more than 6 months at room temperature, which is very convenient for medical personnel to carry and use in specific environments.
  • the recombinant human IFN- ⁇ spray has the characteristics of safety and effectiveness, no stimulation, and low cost, and is suitable for large-scale general population applications.
  • recombinant human IFN- ⁇ as a spray makes full use of the rich microvilli and porous capillaries on the nasal mucosa, allowing the interferon to be well absorbed through the nasal mucosa, and activating the nasal mucosa and adjacent tissues.
  • VER0 cell experiments show that the recombinant human ⁇ interferon of the present invention and IFN- ⁇ have similar anti-SARS virus activity; animal experiments show that the recombinant human ⁇ interferon of the present invention can effectively inhibit the proliferation of SARS virus in cynomolgus monkeys and reduce Damage to the body.
  • the omega drug group includes: 4314 medical staff (high-risk population) in designated hospitals for SARS treatment, 2,181 urban residents in SARS-affected areas, and 1,900 migrant workers returning from the affected areas. The results show that the use of recombinant human omega interferon in the population is Safe and effective in preventing SARS virus infection.
  • the recombinant human ⁇ interferon expression method of the invention has the characteristics of high yield, simple expression and purification, low cost, convenient expansion of production, and the like, and has broad market prospects.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un interféron φ humain recombinant, son procédé d'expression et ses utilisations. L'interféron φ est une protéine ayant les acides aminés résiduels de SEQ ID NO :2 dans la séquence listée, ou une protéine dérivée de la protéine SEQ ID NO :2 par substitution, effacement ou addition d'un ou plusieurs acides aminés dans la séquence d'acides aminés ayant la même activité. Les études expérimentales menées ont démontré que l'interféron φ est sûr pour le corps humain et aide à éviter les infections de SARS efficacement. Le procédé d'expression d'interféron φ s'est avéré à fort rendement, à expression et purification simples et pratiques et à faible coût.
PCT/CN2004/000374 2003-04-25 2004-04-19 Interferon$g(v) humain recombinant, son procede d'expression et ses utilisations WO2004096852A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200480011049.1A CN1777620A (zh) 2003-04-25 2004-04-19 一种重组人ω干扰素及其表达方法与应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN 03123298 CN1444993A (zh) 2003-04-25 2003-04-25 重组人干扰素ω在制备非典型肺炎防治药物中的应用
CN03123298.1 2003-04-25
CN03123299.X 2003-04-25
CNA03123299XA CN1539971A (zh) 2003-04-25 2003-04-25 一种利用基因工程手段制备人干扰素ω的方法

Publications (1)

Publication Number Publication Date
WO2004096852A1 true WO2004096852A1 (fr) 2004-11-11

Family

ID=33419306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2004/000374 WO2004096852A1 (fr) 2003-04-25 2004-04-19 Interferon$g(v) humain recombinant, son procede d'expression et ses utilisations

Country Status (1)

Country Link
WO (1) WO2004096852A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021130537A2 (fr) 2019-12-23 2021-07-01 Versameb Ag Compositions et méthodes pour la modulation de l'expression de gènes de manière simultanée

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204A2 (fr) * 1984-08-01 1986-02-05 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Séquences génétiques, interféron peptide du type I codé par celles-ci et les organismes les produisant
EP0264790A2 (fr) * 1986-10-22 1988-04-27 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Vecteurs d'expression de levures pour IFN-oméga, leur procédé de préparation et leur emploi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204A2 (fr) * 1984-08-01 1986-02-05 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Séquences génétiques, interféron peptide du type I codé par celles-ci et les organismes les produisant
EP0264790A2 (fr) * 1986-10-22 1988-04-27 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Vecteurs d'expression de levures pour IFN-oméga, leur procédé de préparation et leur emploi

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021130537A2 (fr) 2019-12-23 2021-07-01 Versameb Ag Compositions et méthodes pour la modulation de l'expression de gènes de manière simultanée

Similar Documents

Publication Publication Date Title
US7622445B2 (en) Muteins of fibroblast growth factor 21
KR100854198B1 (ko) 섬유아세포 성장 인자 21의 뮤테인
US7915483B2 (en) C-terminally truncated interferon
JPH06508039A (ja) 抗腫瘍治療のためのサイトカインを発現する組換え型欠損アデノウイルス
MX2009001366A (es) Proteinas semejantes a interferon humano recombinante.
Tian et al. Construction and characterization of a potent, long-lasting recombinant human serum albumin-interferon α1 fusion protein expressed in Pichia pastoris
CN113425832A (zh) 干扰素λ在新型冠状病毒(2019-nCoV)感染治疗中的应用
US20220177546A1 (en) Systems and methods for producing collagen 7 compositions
WO2020108427A1 (fr) NOUVEAU INTERFÉRON-α ET SON PROCÉDÉ DE PRÉPARATION, COMPOSITION ET UTILISATION ASSOCIÉES
WO2004096852A1 (fr) Interferon$g(v) humain recombinant, son procede d'expression et ses utilisations
CN113440603B (zh) 人α干扰素亚型及受体结合相关位点突变体在制备防治新型冠状病毒感染药物中的用途
CN114539426A (zh) 一种含干扰素α的融合蛋白、表达该融合蛋白的重组菌株及其制备方法
CN109467597B (zh) 一种新型干扰素及其制备方法、组合物和用途
JP2023522423A (ja) インターフェロンアルファ２バリアント及びその使用
US9421243B2 (en) Therapy for influenza like illness
CN1777620A (zh) 一种重组人ω干扰素及其表达方法与应用
CN113292638A (zh) 用于抗冠状病毒感染的多肽药物及其方法和应用
JP4951177B2 (ja) 抗パラミクソウイルス剤
JP7483853B2 (ja) ｈｎＲＮＰＡ２Ｂ１の抗感染作用及びその応用
EP2647645A1 (fr) Protéines recombinées de Parapoxvirus ovis et compositions pharmaceutiques produites à partir de celles-ci
RU2812047C1 (ru) Вариант интерферона-бета человека с двойной мутацией и способ улучшения стабильности варианта интерферона-бета человека
WO2020108428A1 (fr) Cytokine antivirale humaine de recombinaison, procédé de préparation correspondant, composition et utilisation associées
JP2589094B2 (ja) 抗悪性腫瘍剤
JP2000514066A (ja) 抗ウイルス性抗腫瘍剤としてのインターロイキン―８
TW202334430A (zh) 自酵母菌產生之alpha-1抗胰蛋白酶用於治療病毒感染

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 20048110491

Country of ref document: CN

122 Ep: pct application non-entry in european phase